inVentiv Health More Closely Aligns Clinical Segment to Commercial and Consulting Expertise to Deliver Enhanced, Convergent Clinical Services
inVentiv Health, Inc., offering clinical, commercial, and consulting services to the healthcare industry, today announced that its existing clinical research organization (CRO), PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the Clinical segment and inVentiv’s commercial and consulting services.
“As a top global CRO, renaming ourselves inVentiv Health Clinical demonstrates a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services,” said Paul Meister, Chief Executive Officer at inVentiv Health. “Clients can now access broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialization.”
Industry veteran Raymond Hill was appointed in December to lead inVentiv Health Clinical. Prior to joining inVentiv, Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, Hill was President at IMS Consulting Group, where he oversaw an aggressive strategy of organic and inorganic growth – building the business to $500M in six years. Hill is a graduate of Cornell University and holds a master's degree from Duke University.
“By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry,” said Hill. “One example is our ability to assist clients in Late Stage trials by tapping both digital and adherence experts from other inVentiv companies. Through this approach we can help our clients simplify complex health economics and outcomes research trials.”
inVentiv Health Clinical is a clinical research organization offering Early Stage (Phase I), Phase II-III, Late Stage (Phase IV) clinical development and clinical staffing services to healthcare companies worldwide. These services can be deployed on any scale from highly complex multinational clinical trials to earlier stage studies involving specialized patient populations to Late Stage post-approval studies, or from placing a single individual at a company to outsourcing a full clinical department.
“Healthcare companies are continuing to increase their reliance on CROs,” said Hill. “With 7,000 employees in more than 36 countries across the world, inVentiv Health Clinical has the breadth of experience in geographies and the necessary therapeutic expertise to meet the challenges that our clients are facing.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.